X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined, publicly traded company will focus on the advancement, expansion and commercialization of Aadi’s clinical stage pipeline, including Aadi’s lead program for its nanoparticle albumin-bound mTOR inhibitor, FYARRO™, an mTOR inhibitor bound to human albumin.
Lead Product(s): Nab-sirolimus
Therapeutic Area: Oncology Product Name: Fyarro
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Aadi Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger August 26, 2021
Details:
Following the proposed merger, Aerpio will change its name to “Aadi Bioscience, Inc.” and the combined public company will focus on advancing Aadi’s lead product candidate, FYARROTM (sirolimus albumin-bound nanoparticles for injectable suspension; nab-sirolimus; ABI-009).
Lead Product(s): Nab-sirolimus
Therapeutic Area: Oncology Product Name: Fyarro
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Aadi Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 17, 2021
Details:
The I-SPY COVID Trial was halted by Quantum Leap Healthcare Collaborative because Aerpio's razuprotafib was difficult to administer in the setting of COVID-19, with 30% of patients discontinuing the agent due to disease-related hypotension.
Lead Product(s): Razuprotafib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AKB-9778
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quantum Leap Healthcare
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2021
Details:
Razuprotafib a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase, is being developed as a treatment for open angle glaucoma, and the Company intends to investigate the therapeutic potential of razuprotafib in other indications.
Lead Product(s): Razuprotafib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AKB-9778
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
The study is designed to evaluate the safety and efficacy of a topical ocular formulation of razuprotafib in approximately 195 patients followed over a 28-day period, and patients must undergo a 28-day washout prior to randomization.
Lead Product(s): Razuprotafib
Therapeutic Area: Ophthalmology Product Name: AKB-9778
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2020
Details:
First patient with razuprotafib in the I-SPY COVID Trial, a phase 2 platform trial aimed at improving treatment of acute respiratory distress syndrome (ARDS) in severely ill COVID-19 (adult) patients.
Lead Product(s): Razuprotafib,Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: AKB-9778
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quantum Leap Healthcare
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
Details:
Aerpio is developing a selective small molecule inhibitor of vascular endothelial protein tyrosine phosphatase, razuprotafib (AKB-9778), that restores Tie2 pathway activation in endothelial cells to stabilize blood vessels during vascular injury and inflammation.
Lead Product(s): Razuprotafib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AKB-9778
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: MTEC
Deal Size: $5.1 million Upfront Cash: Undisclosed
Deal Type: Funding August 04, 2020
Details:
Aerpio Pharmaceuticals has commenced patient enrollment in its double-blind, placebo-controlled Phase 2 trial in patients with elevated intraocular pressure (IOP) associated with open angle glaucoma (OAG) or ocular hypertension (OHT).
Lead Product(s): Razuprotafib
Therapeutic Area: Ophthalmology Product Name: AKB-9778
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020
Details:
The collaboration aims at evaluating razuprotafib in a new randomized, investigational treatment arm in the I-SPY COVID Trial for the treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19.
Lead Product(s): Razuprotafib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quantum Leap Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 27, 2020
Details:
The renegotiated licensing deal is intended to place Gossamer Bio in a better position to progress GB004, and in addition, is designed to facilitate the further development of each company’s respective pipelines.
Lead Product(s): GB004
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gossamer Bio
Deal Size: $105.0 million Upfront Cash: $15.0 million
Deal Type: Licensing Agreement May 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
